MASLD and NAFLD Liver Outcomes
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is a major comorbidity of T2D — approximately 25–30% of T2D adults have some degree of MASLD, and a subset progress to metabolic-associated steatohepatitis (MASH, formerly NASH), which carries risk of cirrhosis, liver failure, and hepatocellular carcinoma. Tirzepatide’s mechanisms (weight reduction, insulin sensitisation, direct GIP/GLP-1 receptor effects on hepatocytes) make it biologically plausible as a MASH treatment.
SYNERGY-NASH Phase 2 trial (NEJM 2024, PMID 38856224): In a phase 2 double-blind RCT, patients with biopsy-confirmed MASH and stage F2 or F3 (moderate-to-severe) fibrosis were randomised to tirzepatide (5mg, 10mg, or 15mg once-weekly) or placebo for 52 weeks. Tirzepatide was significantly more effective than placebo for the primary outcome: MASH resolution without worsening of liver fibrosis. A post-hoc subgroup analysis (JHEP Reports 2025) found MASH resolution rates up to 73% in certain subgroups. The investigators noted “larger and longer trials are needed to further assess efficacy and safety.” A Phase 3 trial (SURPASS-LIVER or similar) would be expected. Importantly, SYNERGY-NASH enrolled patients with MASH regardless of whether they had T2D — making it a disease-specific hepatology trial, not a T2D-specific trial.
SURPASS-3 MRI substudy (T2D-specific): In the SURPASS-3 MRI substudy (T2D patients on metformin ± SGLT2i), tirzepatide significantly reduced liver fat content (LFC) and visceral adipose tissue (VAT) volume versus insulin degludec over 52 weeks. This provides direct T2D-population evidence of liver fat reduction, consistent with the SYNERGY-NASH hepatology findings.
Practical relevance for T2D patients: The high prevalence of MASLD in T2D (25-30%) means that for many T2D patients on tirzepatide, liver fat reduction is an additional benefit beyond glycaemic control. In patients with known or suspected MASH (elevated liver enzymes, suggestive FIB-4 score), tirzepatide’s hepatic benefits can be discussed as an added consideration. However, SYNERGY-NASH was Phase 2 (not approved indication), and MASH is not currently in tirzepatide’s licensed indications.
Ontology MASLD NAFLD Outcomes [relates] Tirzepatide MASLD NAFLD Outcomes [relates] Type 2 Diabetes MASLD NAFLD Outcomes [relates] Weight Loss in T2D MASLD NAFLD Outcomes [relates] GIP Receptor Agonism
Evidence Summary
| Study | Population | Outcome | Result | Strength |
|---|---|---|---|---|
| SYNERGY-NASH (NEJM 2024) | MASH F2-F3 (±T2D) | MASH resolution without fibrosis worsening | Superior to placebo; up to 73% resolution | Phase 2 — mixed |
| SURPASS-3 MRI substudy | T2D on metformin ± SGLT2i | Liver fat, VAT reduction | Significantly reduced vs insulin degludec | Substudy — mixed |
Practical Interpretation
- Who this is relevant for: T2D patients with known MASLD (elevated ALT, FIB-4, imaging evidence); the ~25-30% of T2D adults with hepatic comorbidity
- Evidence strength: Phase 2 hepatology trial (promising but not definitive); T2D-specific substudy data
- What remains needed: Phase 3 MASH trial with hard liver endpoints; FDA/EMA approval for MASH indication
- Clinical implication: Tirzepatide has hepatic benefits that can be discussed as additional rationale for use in T2D+MASLD patients
Connections
- Tirzepatide — relates (Phase 2 hepatic evidence; not licensed for MASH)
- Weight Loss in T2D — relates (weight reduction mediates liver fat reduction)
- GIP Receptor Agonism — relates (direct GIP hepatic effects plausible)
- SURPASS-3 — evidence_from (MRI substudy liver fat data)